Clinical Trial Update: A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating BL-M07D1 in combination with pertuzumab versus standard therapy (docetaxel with trastuzumab and pertuzumab) for first-line HER2-posit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BL-M07D1
• DOCETAXEL (DOCETAXEL)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING